BioPharma Resources

Drug Trial Radar · NCT06393374

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,530 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,530

Planned (sponsor's estimate)

Start

Jun 24, 2024

Primary completion

Dec 16, 2030

Study completion Dec 14, 2037

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
May 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare sacituzumab tirumotecan plus pembrolizumab to TPC (pembrolizumab or pembrolizumab plus capecitabine) with respect to invasive disease-free survival (iDFS) per investigator assessment. It is hypothesized that sacituzumab tirumotecan plus pembrolizumab is superior to TPC with respect to iDFS per investigator assessment.

Conditions

  • Triple-Negative Breast Cancer

Interventions

  • PembrolizumabBiological

    Pembrolizumab 400 mg intravenous (IV) infusion q6w

  • Sacituzumab tirumotecanBiological

    Sacituzumab tirumotecan 4 mg/kg IV infusion q2w

  • CapecitabineDrug

    Capecitabine 1000 mg/m\^2 to 1250 mg/m\^2 by mouth BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive Disease-Free Survival (iDFS)Time frame: Up to approximately 77 months

Locations

317 sites in 31 countries. Site status is shown where the registry gives one.

  • Infirmary Cancer Care ( Site 0001)

    Mobile, Alabama · Recruiting

  • Ironwood Cancer & Research Centers-Research ( Site 0054)

    Chandler, Arizona · Recruiting

  • MemorialCare Orange Coast Medical Center ( Site 9501)

    Fountain Valley, California · Recruiting

  • Scripps Cancer Center ( Site 0052)

    La Jolla, California · Recruiting

  • Cancer and Blood Specialty Clinic ( Site 0008)

    Los Alamitos, California · Completed

  • Kaiser Permanente - Oakland ( Site 0079)

    Oakland, California · Recruiting

  • Profound Research LLC ( Site 0105)

    Oceanside, California · Completed

  • Kaiser Permanente - Roseville ( Site 0081)

    Roseville, California · Recruiting

  • Kaiser Permanente - San Francisco ( Site 0080)

    San Francisco, California · Recruiting

  • Kaiser Permanente - Santa Clara ( Site 0082)

    Santa Clara, California · Recruiting

  • Providence Medical Foundation ( Site 9543)

    Santa Rosa, California · Recruiting

  • Kaiser Permanente Vallejo Medical Center ( Site 0060)

    Vallejo, California · Recruiting

  • Kaiser Permanente - Walnut Creek ( Site 0078)

    Walnut Creek, California · Recruiting

  • Bass Medical Group ( Site 0089)

    Walnut Creek, California · Completed

  • Cancer Centers of Colorado St. Mary's Regional Hospital ( Site 0046)

    Grand Junction, Colorado · Recruiting

  • University of Connecticut Health Center ( Site 0128)

    Farmington, Connecticut · Recruiting

  • Yale Cancer Center ( Site 0053)

    New Haven, Connecticut · Recruiting

  • Helen F. Graham Cancer Center & Research Institute ( Site 0018)

    Newark, Delaware · Recruiting

  • AdventHealth Altamonte Springs ( Site 0125)

    Altamonte Springs, Florida · Recruiting

  • Orlando Health Cancer Institute ( Site 0030)

    Orlando, Florida · Recruiting

  • Comprehensive Hematology Oncology ( Site 0091)

    St. Petersburg, Florida · Completed

  • Cleveland Clinic Martin North Hospital ( Site 0114)

    Stuart, Florida · Recruiting

  • Archbold Memorial Hospital-Lewis Hall Singletary Oncology Center ( Site 0040)

    Thomasville, Georgia · Completed

  • Illinois Cancer Specialists (ICS) ( Site 8010)

    Arlington Heights, Illinois · Recruiting

  • Southern Illinois Hospital Services ( Site 9547)

    Carterville, Illinois · Recruiting

  • Orchard Healthcare Research Inc. ( Site 0014)

    Skokie, Illinois · Recruiting

  • Northwest Cancer Center - Dyer Clinic ( Site 0097)

    Dyer, Indiana · Recruiting

  • Parkview Research Center at Parkview Regional Medical Center ( Site 0011)

    Fort Wayne, Indiana · Recruiting

  • Cancer Center of Kansas ( Site 0004)

    Wichita, Kansas · Completed

  • Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0044)

    Edgewood, Kentucky · Recruiting

  • CHRISTUS St. Frances Cabrini Hospital Center for Cancer Care ( Site 0109)

    Alexandria, Louisiana · Recruiting

  • Ochsner LSU Health - Monroe Medical Center, Family Medicine Clinic ( Site 0063)

    Monroe, Louisiana · Completed

  • Louisiana State University Health Sciences Shreveport ( Site 0029)

    Shreveport, Louisiana · Recruiting

  • Holy Cross Hospital ( Site 0069)

    Silver Spring, Maryland · Recruiting

  • University of Michigan ( Site 0103)

    Ann Arbor, Michigan · Recruiting

  • Henry Ford Health ( Site 0010)

    Detroit, Michigan · Recruiting

  • Profound Research LLC ( Site 0074)

    Royal Oak, Michigan · Completed

  • Metro-Minnesota Community Clinical Oncology ( Site 0031)

    Saint Louis Park, Minnesota · Recruiting

  • University of Mississippi Medical Center ( Site 0043)

    Jackson, Mississippi · Recruiting

  • SSM Health Cancer Care - Fenton ( Site 0088)

    Fenton, Missouri · Completed

Showing 40 of 317 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.